Want to see SE:ACE full AI Analyst Report?
Top Page
Ascelia Pharma AB
(ACE)
Select Model
Select Model
Rating:41Neutral
Price Target:
kr0.45
▼(-85.68% Downside)
Action:Upgraded
Date:07/15/26
The score is primarily constrained by weak financial performance (no revenue, sustained losses, and meaningful cash burn) and bearish technical conditions (price below major moving averages with negative MACD and very low RSI). Low balance-sheet leverage provides some stability, but the negative P/E and lack of dividend yield offer limited valuation support.
Positive Factors
Niche product / clinical need
Ascelia’s lead candidate is an oral liver‑MRI contrast targeting patients with severe renal impairment and the company focuses on orphan and hospital specialty medicines. This concentration addresses a durable, clinical unmet need and creates a narrow commercial niche with less mass‑market competition and clearer go‑to‑market targeting over months.
Negative Factors
No revenue / persistent losses
The company remains pre‑revenue with repetitive, sizable net losses (TTM ~71m). Without product sales, profitability depends on successful approval/commercial deals; this structural lack of revenue implies ongoing capital needs, limited visibility to sustainable margins, and elevated execution risk over the next several months.
Read all positive and negative factors
Positive Factors
Negative Factors
Niche product / clinical need
Ascelia’s lead candidate is an oral liver‑MRI contrast targeting patients with severe renal impairment and the company focuses on orphan and hospital specialty medicines. This concentration addresses a durable, clinical unmet need and creates a narrow commercial niche with less mass‑market competition and clearer go‑to‑market targeting over months.
Read all positive factors
Ascelia Pharma AB (ACE) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr71.17M
Dividend YieldN/A
Average Volume (3M)1.75M
Price to Earnings (P/E)―
Beta (1Y)0.63
Revenue GrowthN/A
EPS Growth51.40%
CountrySE
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.59
Shares Outstanding133,535,460
10 Day Avg. Volume1,883,755
30 Day Avg. Volume1,753,338
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.67
Price to Sales (P/S)0.00
P/FCF Ratio-5.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.09
Revenue Forecast (FY)kr52.30M
Ascelia Pharma AB Business Overview & Revenue Model
Company Description
Ascelia Pharma AB (publ) is a Swedish biotechnology company concentrating on the development of orphan drugs for cancer treatment. The firm is currently progressing Mangoral, an innovative non-gadolinium contrast agent, through Phase 3 clinical tr...
How the Company Makes Money
null...
Ascelia Pharma AB Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -888.00K | -938.00K | -1.05M | -3.89M | -8.72M |
| EBITDA | -68.94M | -73.24M | -67.69M | -108.56M | -132.06M | -128.42M |
| Net Income | -70.90M | -76.25M | -80.03M | -109.29M | -131.22M | -125.90M |
Balance Sheet | ||||||
| Total Assets | 96.87M | 111.94M | 140.92M | 87.07M | 218.57M | 333.49M |
| Cash, Cash Equivalents and Short-Term Investments | 33.89M | 49.86M | 75.26M | 21.86M | 149.56M | 261.60M |
| Total Debt | 689.00K | 1.04M | 25.40M | 1.06M | 484.00K | 1.66M |
| Total Liabilities | 13.95M | 12.47M | 61.98M | 12.74M | 37.71M | 25.66M |
| Stockholders Equity | 82.92M | 99.47M | 78.94M | 74.33M | 180.86M | 307.83M |
Cash Flow | ||||||
| Free Cash Flow | -71.25M | -72.31M | -62.84M | -126.79M | -125.33M | -116.60M |
| Operating Cash Flow | -71.19M | -72.25M | -62.84M | -126.79M | -125.26M | -116.56M |
| Investing Cash Flow | -57.00K | -57.00K | 0.00 | 46.00K | -65.00K | -38.00K |
| Financing Cash Flow | 48.23M | 48.21M | 115.19M | -936.00K | -1.10K | 184.87M |
Ascelia Pharma AB Technical Analysis
Negative
3.17
Price Trends
1.87
Negative
2.44
Negative
2.71
Negative
Market Momentum
-0.37
Negative
29.00
Positive
79.99
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACE, the sentiment is Negative. The current price of 3.17 is above the 20-day moving average (MA) of 0.54, above the 50-day MA of 1.87, and above the 200-day MA of 2.71, indicating a neutral trend. The MACD of -0.37 indicates Negative momentum. The RSI at 29.00 is Positive, neither overbought nor oversold. The STOCH value of 79.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ACE.
Ascelia Pharma AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | kr513.70M | 2.80 | 77.69% | ― | ― | ― | |
53 Neutral | kr440.23M | -3.65 | -17.87% | ― | ― | 22.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr209.14M | -4.23 | -13.41% | ― | -68.66% | -137.27% | |
47 Neutral | kr272.10M | -3.47 | -59.93% | ― | ― | 9.40% | |
44 Neutral | kr31.42M | -0.38 | -151.94% | ― | ― | 57.42% | |
41 Neutral | kr71.17M | -0.90 | -72.62% | ― | ― | 51.40% |
* Healthcare Sector Average
SE:ACE
Ascelia Pharma AB
0.61
-4.48
-88.11%
SE:XBRANE
Xbrane Biopharma AB
10.15
-25.53
-71.55%
SE:ISOFOL
Isofol Medical AB
0.80
-0.08
-9.56%
SE:GUARD
Guard Therapeutics International AB
1.35
-18.95
-93.35%
SE:IMMU
Immunicum AB
6.87
-1.13
-14.12%
SE:CANTA
Cantargia AB
1.80
-1.35
-42.95%
Ascelia Pharma AB Corporate Events
Ascelia Pharma Restructures and Cuts Costs to Sharpen Focus on Orviglance
Jul 15, 2026
Ascelia Pharma has announced organizational changes and cost reduction measures, including the planned departure of Chief Financial Officer Anton Hansson in late August 2026 and a restructuring that will see the finance function report directly to...
Ascelia Pharma Defends Orviglance Data After FDA Complete Response Letter
Jul 12, 2026
Ascelia Pharma has provided an update on its MRI contrast agent candidate Orviglance after the U.S. Food and Drug Administration issued a Complete Response Letter on its New Drug Application. The company maintains that its pivotal phase 3 SPARKLE ...
Ascelia Pharma Receives FDA Complete Response Letter on Orviglance NDA
Jul 3, 2026
Ascelia Pharma AB, a Malmö-based biotech company focused on orphan oncology treatments for rare cancer-related conditions, is advancing a pipeline led by its drug candidates Orviglance and Oncoral. Listed on Nasdaq Stockholm under ticker ACE,...
Ascelia Pharma Bolsters Orviglance Franchise with New Patent Filing
Jun 30, 2026
Ascelia Pharma has filed a new patent application covering packaging and manufacturing innovations for its first-in-class liver imaging drug Orviglance, designed to improve usability for patients and healthcare professionals. The anticipated paten...
Ascelia Showcases Orviglance MRI Data at ESGAR 2026 Amid FDA Review
Jun 9, 2026
Ascelia Pharma said new clinical data for its manganese-based oral MRI contrast agent Orviglance are being presented today at the ESGAR 2026 radiology congress in Montpellier, France. The oral and poster presentations, based on re-analyses of two ...
Ascelia Pharma Nears FDA Decision on Orviglance and Bolsters Finances for Partnering Push
May 12, 2026
Ascelia Pharma reports that FDA review of its New Drug Application for Orviglance is progressing on schedule ahead of the July 3 PDUFA decision date, supported by nine clinical studies, including the pivotal Phase 3 SPARKLE trial showing significa...
Ascelia Pharma AGM Backs Incentive Plan but Rejects Share Issue Mandate
May 4, 2026
Ascelia Pharma AB’s annual general meeting on 4 May 2026 approved the 2025 accounts and decided to carry forward SEK 13.4 million without paying a dividend, while granting discharge from liability to the board and CEO. Shareholders re-electe...
Ascelia Pharma Expands Share Capital After Directed New Issue
Apr 30, 2026
Ascelia Pharma AB has increased its registered number of shares and votes following a directed new issue of ordinary shares completed in April 2026. As of 30 April 2026, the company has a total of 134,569,246 shares outstanding, comprising 133,535...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.